December 2021: mdm2 gene amplification in luminal breast cancer


A biomarker analysis in luminal breast cancer using a humanized tumor mouse (HTM) model has been published in International Journal of Cancer.

First objective of this study was the hypothesis-driven discovery of biomarkers involved in tumor progression upon xenotransplantation of luminal, i.e., estrogen receptor (ER)-positive breast cancer (BC) into humanized mice. The second objective was the marker validation and correlation with the clinical outcome of luminal breast cancer patients from the GeparTrio trial.

• An mdm2 gene amplification propels growth and progression of ER-positive breast cancer in a preclinical humanized tumor mouse (HTM) model, which replicates a functional human immune system
• mdm2 inhibition of ER-positive BC cells in vitro reduces cell proliferation and migration and induces tumor cell apoptosis.
• An unfavorable impact of an mdm2 gain on survival outcome of luminal BC patients is mainly caused within the luminal-A BC subcohort.
• Prospective studies are required to verify the suitability of mdm2 for advanced Luminal BC stratification and therapeutic targeting of ER-positive BC.

Conclusion: We provide evidence for an enhanced luminal BC stratification based on mdm2. Moreover, mdm2 can potentially be utilized as a therapeutic target in the luminal subtype.

Wege AK, Rom-Jurek EM, Jank P, et al. mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease. Int J Cancer. 2021; doi: 10.1002/ijc.33911.


  • 18.11.2022 Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...
  • 10.11.2022 Deutscher Krebskongress

    Deutscher Krebskongress

    Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.

    Mehr ...
  • 08.11.2022 GBG research at SABCS 2022

    GBG research at SABCS 2022

    We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

    Mehr ...
  • 14.10.2022 Location of Subcutaneous Trastuzumab Injection

    Location of Subcutaneous Trastuzumab Injection

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd